Gilead Sciences, Inc. (GILD) Wins FDA Approval for World’s First Twice-Yearly HIV Preventive Therapy

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Gilead Sciences, Inc. is placed seventh among them.

Gilead Sciences, Inc. (NASDAQ:GILD) is making headlines with a breakthrough in HIV prevention following the FDA approval of Yeztugo, the world’s first twice-yearly preventive treatment. This milestone not only strengthens Gilead’s leadership in antiviral innovation but also signals a transformative step in global health and market growth.

Headquartered in Foster City, California, Gilead Sciences, Inc. (NASDAQ:GILD) operates in more than 35 countries with a diverse portfolio spanning HIV, viral hepatitis, cancer, and COVID-19. The corporation’s core advantage lies in its rapid drug development and robust pipeline, particularly in antiviral and oncology therapeutics.

The launch of Yeztugo has already demonstrated strong uptake, with the business aiming to secure 75% insurer coverage within six months and expand access within a year. Its HIV portfolio, including the blockbuster therapy Biktarvy, also continues to perform well, showing a 7% year-over-year sales increase driven by market demand and clinical efficacy.

Gilead Sciences, Inc. (GILD) Wins FDA Approval for World’s First Twice-Yearly HIV Preventive Therapy

Momentum is building globally, with the European Medicines Agency recently recommending approval for lenacapavir, Gilead Sciences, Inc. (NASDAQ:GILD)’s twice-yearly HIV prevention drug, which could soon achieve market exclusivity in Europe. Broader access through WHO-backed initiatives may also extend availability to lower-income regions, reinforcing the firm’s global health impact.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.